Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

        .1.1 Patients with refractory BK infection post allogeneic HSCT, post solid organwith primary immunodeficiencies with eitherg urine and/or plasma BK RT-PCR DNA (by 1 log) after 7 days or persistentquantitative qRT-PCR DNA copies after 14 days despite two weeks of appropriateviral therapy AND/ORdical intolerance to anti-viral therapies including:2 renal toxicity with cidofovir or other > grade 2 toxicities secondary todofovir And/orknown resistance to cidofovir 1.2. Consent: Written informed consent given (by patientgal representative) prior to any study-related procedures.1.3 Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs) 1.4 Age: 0.1 to 30.99years 1.5 Females of childbearing potential with a negative urine pregnancy testusion:1. Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of BK CTLusion2. Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of BK CTLusion3. Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to BK CTLusion. Thymoglobulin (ATG) or Alemtuzumab within 30 days5. Patient with poor performance status determined by Karnofsky (patients >16 years) orLansky (patients ≤16 years) score ≤30%6. Concomitant enrollment in another experimental clinical trial investigating they BK infection.7. Any medical condition which could compromise participation in the study according tohe investigator's assessment8. Known HIV infection9. Female patient of childbearing age who is pregnant or breast-feeding or not willing touse an effective method of birth control during study treatment.10. Known hypersensitivity to iron dextran11. Patients unwilling or unable to comply with the protocol or unable to give informed.12. Known human anti-mouse antibodies